COVID-19: Vaccines and Therapeutics

A research letter published in the New England Journal of Medicine looks at delayed injection-site skin reactions to the Moderna COVID-19 vaccine four to 11 days after 12 people received the first dose.
The National Institutes of Health has halted a clinical trial evaluating the effectiveness of COVID-19 convalescent plasma in emergency department patients with mild-to-moderate COVID-19 symptoms and at least one risk factor for severe COVID-19 after an independent board concluded from the data…
President Biden today announced a major partnership between Johnson & Johnson and Merck to manufacture the latest COVID-19 vaccine to be authorized for emergency use in the U.S.
The federal government has agreed to purchase at least 100,000 doses of the combination monoclonal antibody therapy bamlanivimab and etesevimab, Eli Lilly and Company announced.
The Food and Drug Administration granted an emergency use authorization for Johnson & Johnson’s single-dose COVID-19 vaccine.
The House of Representatives early this morning voted 219-212 to approve a modified version of the American Rescue Plan Act of 2021, legislation to provide reconciliation protection for a roughly $1.9 trillion COVID-19 relief package, which includes a number of provisions that affect hospitals and…
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee recommended the approval of Johnson & Johnson’s COVID-19 vaccine candidate.
Israeli patients aged 70 and older were much less likely to require mechanical ventilation for COVID-19 after most people in their age group had received the second dose of the Pfizer vaccine, according to a study released by the Centers for Disease Control and Prevention.
AHA released a one-stop web hub for hospitals and health systems to find communication resources related to COVID-19 vaccines.